MENU
+Compare
EOLS
Stock ticker: NASDAQ
AS OF
Oct 27, 02:59 PM (EDT)
Price
$7.29
Change
+$0.51 (+7.51%)
Capitalization
439.21M

EOLS stock forecast, quote, news & analysis

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market... Show more

EOLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. EOLS showed earnings on August 05, 2025. You can read more about the earnings report here.
Interact to see
Advertisement
A.I.Advisor
a Summary for EOLS with price predictions
Oct 24, 2025

Aroon Indicator for EOLS shows an upward move is likely

EOLS's Aroon Indicator triggered a bullish signal on October 24, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 204 similar instances where the Aroon Indicator showed a similar pattern. In of the 204 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where EOLS's RSI Indicator exited the oversold zone, of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on October 20, 2025. You may want to consider a long position or call options on EOLS as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for EOLS just turned positive on October 02, 2025. Looking at past instances where EOLS's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

EOLS moved above its 50-day moving average on October 24, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EOLS advanced for three days, in of 281 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EOLS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

EOLS broke above its upper Bollinger Band on October 20, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. EOLS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EOLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: EOLS's P/B Ratio (114.943) is slightly higher than the industry average of (17.235). P/E Ratio (0.000) is within average values for comparable stocks, (73.350). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.089). EOLS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.031). P/S Ratio (1.556) is also within normal values, averaging (47.635).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Tilray Brands (NASDAQ:TLRY), BioCryst Pharmaceuticals (NASDAQ:BCRX), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.05B. The market cap for tickers in the group ranges from 2.12K to 64.68B. ZTS holds the highest valuation in this group at 64.68B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -0%. For the same Industry, the average monthly price growth was 2%, and the average quarterly price growth was 38%. HYEX experienced the highest price growth at 58%, while MILFF experienced the biggest fall at -61%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -40%. For the same stocks of the Industry, the average monthly volume growth was -15% and the average quarterly volume growth was -11%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 65
Price Growth Rating: 56
SMR Rating: 81
Profit Risk Rating: 90
Seasonality Score: 0 (-100 ... +100)
View a ticker or compare two or three
EOLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a manufacturer of neurotoxins

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
520 Newport Center Drive
Phone
+1 949 284-4555
Employees
273
Web
https://www.evolus.com